ORKUN AYDİN, PİNAR UNAL-AYDİN
Psychiatry and Behavioral Sciences - 2017;7(4):234-236
Hyperprolactinemia is a severe problem which involves galactorrhea, amenorrhea, sexual dysfunction, and lowered bone mineral density. It can be a long-lasting problem belongs to the atypical antipsychotics that impairs treatment adherence and quality of life in patients with schizophrenia. The paliperidone palmitate may cause hyperprolactinemia and there are different approaches in management of this adverse event. Adding oral aripiprazole was shown to be useful in the treatment of hyperprolactinemia due to paliperidone palmitate. Now the new drug long-acting Injectable (LAI) aripiprazole may become a possible new agent in treatment of schizophrenia patients with paliperidone palmitate induced hyperprolactinemia.
